Table 3: Patients with long-term survival.
|
Case 1 |
Case 2 |
Case 3 |
Case 4 |
Case 5 |
|
|
gender |
male |
male |
female |
male |
male |
|
age |
19 |
24 |
24 |
30 |
48 |
|
main complain |
fatigue |
fever |
Fever, lymph node enlargement |
fatigue |
recurrent abdominal pain |
|
WBC（/L） |
102.77×109 |
71.4×109 |
107.73×109 |
4.03×109 |
27.8×109 |
|
Hb（g/L） |
60 |
125 |
61 |
86 |
93 |
|
PLT（/L） |
59×109 |
230×109 |
56×109 |
37×109 |
106×109 |
|
marrow blast |
94% |
71.5% |
77% |
90.4% |
95.5% |
|
Flow
cytometry analysis |
CD58，CD66，CD34，CD10，CD19，CD45 |
HLA-DR，CD10，CD19，CD20，CD22，CD38，CD123，CD79a，TdT |
CD19，CD10，CD33，CD38，CD22，CD79a，HLA-DR |
CD79a，CD22，CD19，CD10， |
CD34，CD79a，
CD19，CD10 |
|
chromosome |
41-46，XY，9P-[CP7]/45，XY，9P-/46，XY |
46，XY，t（9，22）（q34；q11.2） |
47，XX，t（1:11）（p36.1:q21），+21[8]/46，XX[1] |
44，XY，-7，t(9;22)(q34;q11)，-13[15]/46，XY[5] |
46，XY，t（9，22）（q34；q11.2） |
|
gene |
BCR/ABL（p210） |
BCR/ABL（p190） |
BCR/ABL |
||
|
induction therapy |
VDCLP |
VDCP+ dasatinib |
VDCLP |
hyper-CVAD+ imatinib |
VDCLP+ dasatinib |
|
HSCT |
umbilical
cord blood transplantation was performed 4.5 months after diagnosis during
CR1 |
allo-HSCT
was performed 5 months after diagnosis during CR1 |
allo-HSCT
was performed 3 months after diagnosis during CR1 |
allo-HSCT
was performed 4.5 months after diagnosis during CR1 |
allo-HSCT
was performed 4.5 months after diagnosis during CR1 |